ANIP Q2 2025 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$211M+53.1% YoY

Gross Profit

$137M64.7% margin

Operating Income

$14M6.6% margin

Net Income

$9M4.0% margin

EPS (Diluted)

$0.36

QoQ Revenue Growth

+7.2%

Cash Flow

Operating Cash Flow

$76M

Free Cash Flow

$69M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$881M

Stockholders' Equity

$462M

Cash & Equivalents

$218M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$211M	$138M	+53.1%
Gross Profit	$137M	$80M	+70.2%
Operating Income	$14M	$5M	+168.8%
Net Income	$9M	-$2M	+473.8%

Revenue Segments

Sales of rare disease pharmaceutical products

$104M49%

Total Sales of Generics and Other

$94M45%

Sales of Established Brands

$13M6%